Nkarta (NKTX) Receivables - Other (2019 - 2026)

Nkarta's quarterly Receivables - Other came in at $1.7 million in Q1 2026, down 29.17% year-on-year from $2.4 million in Q1 2025, and down 15.0% quarter-over-quarter from $2.0 million in Q4 2025.

Nkarta has reported Receivables - Other for 8 years, with the latest figure at $1.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Receivables - Other fell 29.17% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 29.17% YoY), and the FY2025 full-year result was $2.0 million, down 20.0% from the prior year.
  • Receivables - Other for Q1 2026 stood at $1.7 million, down from $2.0 million in the prior quarter.
  • The five-year high for Receivables - Other was $2.5 million in Q3 2024, with the low at $600000.0 in Q1 2023.
  • Average Receivables - Other over 5 years is $1.6 million, with a median of $1.3 million recorded in 2022.
  • Year-over-year, Receivables - Other plunged 40.0% in 2023 and soared 177.78% in 2024.
  • Tracing NKTX's Receivables - Other over 5 years: stood at $800000.0 in 2022, then soared by 50.0% to $1.2 million in 2023, then soared by 108.33% to $2.5 million in 2024, then declined by 20.0% to $2.0 million in 2025, then decreased by 15.0% to $1.7 million in 2026.
  • The last three Receivables - Other figures came in at $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Nkarta 232.80 Mn 232.80 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.70 Mn
Mar 31, 2026 1.70 Mn
Dec 31, 2025 2.00 Mn
Dec 31, 2025 2.00 Mn
Sep 30, 2025 2.10 Mn
Sep 30, 2025 2.10 Mn
Jun 30, 2025 2.20 Mn
Jun 30, 2025 2.20 Mn
Mar 31, 2025 2.40 Mn
Mar 31, 2025 2.40 Mn
Dec 31, 2024 2.50 Mn
Dec 31, 2024 2.50 Mn
Sep 30, 2024 2.50 Mn
Sep 30, 2024 2.50 Mn
Jun 30, 2024 2.10 Mn
Jun 30, 2024 2.10 Mn
Mar 31, 2024 1.20 Mn
Mar 31, 2024 1.20 Mn
Dec 31, 2023 1.20 Mn
Dec 31, 2023 1.20 Mn
Sep 30, 2023 900,000.00
Sep 30, 2023 900,000.00
Jun 30, 2023 900,000.00
Jun 30, 2023 900,000.00
Mar 31, 2023 600,000.00
Mar 31, 2023 600,000.00
Dec 31, 2022 800,000.00
Dec 31, 2022 800,000.00
Sep 30, 2022 1.30 Mn
Sep 30, 2022 1.30 Mn
Jun 30, 2022 1.00 Mn
Jun 30, 2022 1.00 Mn
Mar 31, 2022 1.00 Mn
Mar 31, 2022 1.00 Mn
Dec 31, 2021 1.00 Mn
Dec 31, 2021 1.00 Mn
Sep 30, 2021 900,000.00
Sep 30, 2021 900,000.00
Jun 30, 2021 1.40 Mn
Jun 30, 2021 1.40 Mn
Mar 31, 2021 800,000.00
Mar 31, 2021 800,000.00
Dec 31, 2020 1.10 Mn
Dec 31, 2020 1.10 Mn
Sep 30, 2020 300,000.00
Sep 30, 2020 300,000.00
Dec 31, 2019 41,000.00
Dec 31, 2019 41,000.00